149 related articles for article (PubMed ID: 37983638)
1. Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma.
Barrière S; Faure-Conter C; Leblond P; Philippe M; des Portes V; Lion François L; de Bellescize J; Sabatier I
Epileptic Disord; 2024 Feb; 26(1):133-138. PubMed ID: 37983638
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1.
Cantor E; Meyer A; Morris SM; Weisenberg JLZ; Brossier NM
Childs Nerv Syst; 2022 Nov; 38(11):2245-2249. PubMed ID: 35648241
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
4. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K
Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491
[TBL] [Abstract][Full Text] [Related]
5. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract][Full Text] [Related]
7. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
8. An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS; Blakeley J; Rodriguez FJ
Acta Neuropathol; 2020 Apr; 139(4):625-641. PubMed ID: 30963251
[TBL] [Abstract][Full Text] [Related]
9. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y
Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors.
Hummel L; Ameri M; Alqahtani S; Sadighi Z; Al-Zubidi N
Curr Oncol; 2024 May; 31(5):2644-2649. PubMed ID: 38785480
[TBL] [Abstract][Full Text] [Related]
11. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.
Warrington NM; Gianino SM; Jackson E; Goldhoff P; Garbow JR; Piwnica-Worms D; Gutmann DH; Rubin JB
Cancer Res; 2010 Jul; 70(14):5717-27. PubMed ID: 20551058
[TBL] [Abstract][Full Text] [Related]
12. Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.
Bolcekova A; Nemethova M; Zatkova A; Hlinkova K; Pozgayova S; Hlavata A; Kadasi L; Durovcikova D; Gerinec A; Husakova K; Pavlovicova Z; Holobrada M; Kovacs L; Ilencikova D
Neoplasma; 2013; 60(6):655-65. PubMed ID: 23906300
[TBL] [Abstract][Full Text] [Related]
13. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.
Tang Y; Gutmann DH
Cancer Manag Res; 2023; 15():667-681. PubMed ID: 37465080
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
16. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects.
Hsieh HY; Fung HC; Wang CJ; Chin SC; Wu T
Seizure; 2011 Oct; 20(8):606-11. PubMed ID: 21621428
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis 1-associated optic pathway gliomas.
Shofty B; Ben Sira L; Constantini S
Childs Nerv Syst; 2020 Oct; 36(10):2351-2361. PubMed ID: 32524182
[TBL] [Abstract][Full Text] [Related]
18. Identification of Mutation Regions on
Xu M; Xiong H; Han Y; Li C; Mai S; Huang Z; Ai X; Guo Z; Zeng F; Guo Q
Front Genet; 2018; 9():270. PubMed ID: 30087692
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.
Helfferich J; Nijmeijer R; Brouwer OF; Boon M; Fock A; Hoving EW; Meijer L; den Dunnen WF; de Bont ES
Crit Rev Oncol Hematol; 2016 Aug; 104():30-41. PubMed ID: 27263935
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
Kotch C; Avery R; Getz KD; Bouffet E; de Blank P; Listernick R; Gutmann DH; Bornhorst M; Campen C; Liu GT; Aplenc R; Li Y; Fisher MJ
Neuro Oncol; 2022 Aug; 24(8):1377-1386. PubMed ID: 35018469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]